Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Combination of MIG (CXCL9) chemokine gene therapy with low-dose cisplatin improves therapeutic efficacy against murine carcinoma

Published:2006-05-04 Issue:17 Volume:13 Page:1263-1271
ISSN:0969-7128
Container-title:Gene Therapy
language:en
Short-container-title:Gene Ther

Author:

Zhang R,Tian L,Chen L-J,Xiao F,Hou J-M,Zhao X,Li G,Yao B,Wen Y-J,Li J,Zhang L,Chen X-C,Luo F,Peng F,Jiang Y,Wei Y-Q

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/3302756.pdf

Reference49 articles.

1. Kerbel RS, Klement G, Pritchard KI, Kamen B . Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002; 13: 12–15.

2. Kamen BA, Rubin E, Aisner J, Glatstein E . High-time chemotherapy or high time for low dose. J Clin Oncol 2000; 18: 2935–2937.

3. Gasparini G . Metronomic scheduling: the future of chemotherapy? Lancet Oncol 2001; 2: 733–740.

4. Boehm T, Folkman J, Browder T, O'Reilly MS . Anti-angiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997; 390: 404–407.

5. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15–R24.

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma;2024

2. Gene-activating nanomedicine for the tumor-oriented infiltration of T cells to enhance immunotherapy against solid tumors;Nano Today;2023-10

3. Deactivation of ligand-receptor interactions enhancing lymphocyte infiltration drives melanoma resistance to Immune Checkpoint Blockade;2023-09-22

4. Engineering tumor-specific gene nanomedicine to recruit and activate T cells for enhanced immunotherapy;Nature Communications;2023-04-08

5. HDAC3 Inhibition Promotes Antitumor Immunity by Enhancing CXCL10-Mediated Chemotaxis and Recruiting of Immune Cells;Cancer Immunology Research;2023-02-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3